Erica Surya Klaassen (Erica S Klaassen, Erica Klaassen)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Venues

Clinical and translational science

JMIR research protocols

Strabismus

CHDR

Free University (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

CHDR Feb 15 2010

Netherlands

Statistician :: Statistics

Education History

Free University

Netherlands

MSC :: Mathematics and statistics

Publications

Eva Thijssen, Bert Tuk, Michel Cakici, Veerle van Velze, Erica Surya Klaassen, Frans Merkus, Teus van Laar, Philip H C Kremer, Geert Jan Groeneveld
Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients. Clinical and translational science 17 (5) (2024)
Eva Thijssen, Bert Tuk, Michel Cakici, Veerle van Velze, Erica Surya Klaassen, Frans Merkus, Teus van Laar, Philip H C Kremer, Geert Jan Groeneveld
Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients. Clinical and translational science 17 (5) (2024)
Eva Thijssen, Bert Tuk, Michel Cakici, Veerle van Velze, Erica Surya Klaassen, Frans Merkus, Teus van Laar, Philip H C Kremer, Geert Jan Groeneveld
Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients. Clinical and translational science 17 (5) (2024)
Sebastiaan J W van Kraaij, Diana R Pereira, Bastiaan Smal, Luciana Summo, Anne Konkel, Janine Lossie, Andreas Busjahn, Tom N Grammatopoulos, Erica Surya Klaassen, Robert Fischer, Wolf-Hagen Schunck, Pim Gal, Matthijs Moerland
Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease. Clinical and translational science (2023)
Sebastiaan J W van Kraaij, Pim Gal, Laura G J M Borghans, Erica Surya Klaassen, Francis Dijkstra, Christopher Winrow, Chad Glasser, Geert Jan Groeneveld
First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clinical and translational science (2023)
Sebastiaan J W van Kraaij, Pim Gal, Laura G J M Borghans, Erica Surya Klaassen, Francis Dijkstra, Christopher Winrow, Chad Glasser, Geert Jan Groeneveld
First-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clinical and translational science (2023)
Helena Maria van Minderhout, Maurits Victor Joosse, Erica Surya Klaassen, Nicoline Elisabeth Schalij-Delfos
EEG changes as an indication of central nervous system involvement following cyclopentolate 1% eye drops; a randomized placebo-controlled pilot study in a pediatric population. Strabismus (2023)
Tessa Niemeyer-van der Kolk, Salma Assil, Thomas P Buters, Melanie Rijsbergen, Erica Surya Klaassen, Gary Feiss, Edwin Florencia, Errol P Prens, Jacobus Burggraaf, Martijn B A van Doorn, Robert Rissmann, Matthijs Moerland
Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers. Clinical and translational science 13 (3) (2020)
Jolien Fleur Leijenaar, Geert Jan Groeneveld, Wiesje Maria van der Flier, Philip Scheltens, Erica Surya Klaassen, Henry Chanoch Weinstein, Geert Jan Biessels, Frederik Barkhof, Niels Daniël Prins
Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR research protocols 7 (3) (2018)

Erica Surya Klaassen.css-eqlu8i{font-size:small;padding-left:4px;} (Erica S Klaassen, Erica Klaassen)

Publication Activity (10 Years)

Top Topics

Top Venues

Erica Surya Klaassen (Erica S Klaassen, Erica Klaassen)